YK Bioventures Opportunities GP I, LLC 13D and 13G filings for CERo Therapeutics Holdings, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-12-17 7:26 pm Sale |
2024-12-13 | 13G | CERo Therapeutics Holdings, Inc. CERO |
YK Bioventures Opportunities GP I, LLC | 170 0.000% |
-226,038 (-99.92%) |
Filing |
| 2024-11-14 8:18 pm Purchase |
2024-08-02 | 13G | CERo Therapeutics Holdings, Inc. CERO |
YK Bioventures Opportunities GP I, LLC | 226,208 15.000% |
226,208 (New Position) |
Filing |